W. Amery, Prophylactic and curative treatment of migraine with calcium antagonists, Drugs Design and Delivery, vol.4, pp.197-203, 1989.

A. Zeneca, Zomig? 2,5 mg. Information scientifique -Mentions légales complètes, 2000.

A. Bardley-elliot and N. S. Eletriptan, Eletriptan, CNS Drugs, vol.12, issue.4, pp.325-333, 1999.
DOI : 10.2165/00023210-199912040-00006

J. Baron, Physiopathologie de la migraine : apport de l'in1agerie physiologique, Rev Neurol, vol.156, pp.15-23, 2000.

F. Boureau, L. Kappos, J. Schoenen, P. Esperanca, and E. Ashford, A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine, !nt J Clin Oract, vol.54, issue.5, pp.281-286, 2000.

M. Bousser and H. Massiou, La conduite du traitement de la migraine, Pathol Bio!, vol.40, issue.4, pp.406-412, 1992.

R. Brogden, R. Pinder, P. Sawyer, T. Speight, and G. Avery, Low-Dose Clonidine, Drugs, vol.10, issue.5-6, pp.357-365, 1975.
DOI : 10.2165/00003495-197510050-00006

J. Burkiewicz, J. Chan, and A. B. Eletriptan, Serotonine 5-HT 18110 receptor agonist for the acute treatment of migraine, Formulary, vol.35, pp.129-141, 2000.

J. Campbell, D. Penzien, and E. Wall, Evidence-based guidelines for migraine headache behavioral and physical treatments

C. Cariou, I. Walus, and B. Tourniaire, Epidémiologie de la migraine chez l' enfant âgé de 5 à 12 ans scolarisé à Paris

C. Colucci-d-'amato, V. Pizza, T. Marmolo, E. Giordano, V. Alfano et al., Fluoxetine for Migraine Prophylaxis: A Double-Blind Trial, Headache: The Journal of Head and Face Pain, vol.39, issue.10, pp.716-719, 1999.
DOI : 10.1046/j.1526-4610.1999.3910716.x

J. Couch and R. Hassanein, Amitriptyline in Migraine Prophylaxis, Archives of Neurology, vol.36, issue.11, pp.695-699, 1979.
DOI : 10.1001/archneur.1979.00500470065013

C. Amato, V. Pizza, T. Marmolo, E. Giordano, V. Alfano et al., Fluoxetine for Migraine Prophylaxis: A Double-Blind Trial, Headache: The Journal of Head and Face Pain, vol.39, issue.10, pp.716-719, 1999.
DOI : 10.1046/j.1526-4610.1999.3910716.x

C. Dahlof, D. Boswell, and P. Winter, A comparison of the efficacy, safety and tolerability of naratriptan and sumatriptan, Cephalalgia, vol.17, pp.426-167, 1997.

C. Dahlof, P. Winter, H. Whitehouse, and H. Hassani, Randomized, double-blind, placebocontrolled comparison of oral naratriptan and oral sumatriptan in the acute treatment of migraine, Neurology, vol.48, issue.3, 1997.

D. Boucker and T. , Echelles et classifications La classification des céphalées de l'Intemational Headache Society, Rev Neural, vol.156, issue.2, pp.187-191, 2000.

S. Demirkaya, D. B. Vural-0, and M. Topcuoglu, Efficacy of Intravenous Magnesium Sulfate in the Treatment of Acute Migraine Attacks, Headache: The Journal of Head and Face Pain, vol.311, issue.2, pp.171-177, 2001.
DOI : 10.1016/0002-9149(90)91280-J

D. Trapani, G. Mei, D. Marra, C. Mazza, S. Capuano et al., Gabapentin in the prophylaxis of llllgrame : a double-blind randomized placebo-controlled study, Clin Ther, vol.151, pp.145-148, 2000.

H. Diener, M. Foh, and C. Iaccarino, Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol, Cephalalgia, vol.16, issue.6, pp.441-485, 1996.
DOI : 10.1046/j.1468-2982.1996.1606441.x

H. Diener, E. Hartung, and J. Chrubasik, A comparative study of oral acetylsalicyclic acid and metoprolol for the prophylactic treatment of migraine. A randomized, controlled, double-blind, parallel group phase III study, Cephalalgia, vol.67, issue.2, pp.120-128, 2001.
DOI : 10.1046/j.1468-2982.1996.1606441.x

H. Diener, P. Krupp, J. Schmitt, G. Steitz, K. Milde et al., Cyclandelate in the prophylaxis of migraine:a placebo-controlled study, Cephalalgia, vol.12, issue.1, pp.66-70, 2001.
DOI : 10.1046/j.1468-2982.1996.1606441.x

H. Diener, P. Tfelt-hansen, D. Beukelaar, and F. , The efficacy and safety of sc

A. Vs, sc Sumatriptan in the acute treatment of migraine : a randomized, doubleblind , placebo-controlled trial, Cephalalgia, vol.21, issue.6, pp.672-679, 2001.

M. Dooley, F. Ids, and D. Rizatriptan, A review of its efficacy in the management of migraine

V. Dousset, P. Henry, and P. Michel, Epidémiologie des céphalées, Rev Neural, vol.156, pp.24-29, 2000.

A. Ducros, Génétique de la migraine, Pathol Bio!, vol.48, pp.658-662, 2000.
DOI : 10.2165/00023210-200620001-00003

E. Ernst, Homeopathic Prophylaxis of Headaches and Migraine? A Systematic Review, Journal of Pain and Symptom Management, vol.18, issue.5, pp.353-357, 1999.
DOI : 10.1016/S0885-3924(99)00095-0

M. Ferrari and . La-migraine, Migraine, The Lancet, vol.351, issue.9108, pp.1043-1051, 1998.
DOI : 10.1016/S0140-6736(97)11370-8

URL : https://hal.archives-ouvertes.fr/hal-00625926

G. Géraud, J. Olesen, and V. Pfaffenrath, Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design, Cephalalgia, vol.109, issue.1, pp.30-38, 2000.
DOI : 10.1046/j.1468-2982.1997.1701037.x

G. Géraud and C. Valette, Sumatriptan 20 mg administré par voie nasale : efficacité, tolérance et qualité de vie des patients migraineux, Rev Neural, vol.156, pp.6-7, 2000.

J. Gillis, P. Benfield, and K. Goa, Transnasal Butorphanol, Drugs, vol.50, issue.1, pp.157-175, 1995.
DOI : 10.2165/00003495-199550010-00010

P. Goadsby, A triptan too far?, Journal of Neurology, Neurosurgery & Psychiatry, vol.64, issue.2, pp.143-147, 1998.
DOI : 10.1136/jnnp.64.2.143

P. Goadsby, Rizatriptan in acute treatment of migraine: update on new comparative data *, Cephalalgia, vol.51, issue.Supplement 1, pp.10-15, 2000.
DOI : 10.1159/000008094

P. Goadsby, M. Ferrari, and J. Olesen, Eletriptan in acute migraine: A double-blind, placebo-controlled comparison to sumatriptan, Neurology, vol.54, issue.1, pp.156-163, 2000.
DOI : 10.1212/WNL.54.1.156

P. Goadsby and R. Hargreaves, Mechanisms of action of serotonine 5-HT 18110 agonists : insights into migraine pathophysiology using rizatriptan, Neurology, vol.55, pp.8-14, 2000.

J. Goldstein, C. Dahlof, and H. Diener, Alniditan in the Acute Treatment of Migraine Attacks: A Subcutaneous Dose-Finding Study, Cephalalgia, vol.16, issue.7, pp.497-502, 1996.
DOI : 10.1046/j.1468-2982.1996.1607497.x

J. Gras, C. 1. Llenas, J. Palacios, and J. , Cardiovascular safety profile of almotriptan, a new indolic derivative for the treatment of migraine, European Journal of Pharmacology, vol.410, issue.1, pp.53-59, 2000.
DOI : 10.1016/S0014-2999(00)00878-5

N. Gunasekara, L. Wiseman, and . Naratriptan, Naratriptan, CNS Drugs, vol.8, issue.5, pp.402-408, 1997.
DOI : 10.2165/00023210-199708050-00006

H. Hakkarainen, H. Quiding, and O. Stockman, Mild Analgesics as an Alternative to Ergotamine in Migraine. A Comparative Trial with Acetylsalicylic Acid, Ergotamine Tartrate, and a Dextropropoxyphene Compound, The Journal of Clinical Pharmacology, vol.70, issue.10, pp.590-595, 1980.
DOI : 10.1002/j.1552-4604.1980.tb01674.x

M. Hamatainen, K. Hoppu, E. Valkeila, and P. Santavuori, Ibuprofen or Acetaminophen for the Acute Treatment of Migraine in Children: A Double-blind, Randomized, Placebo-controlled, Crossover Study, Neurology, vol.48, issue.1, pp.103-107, 1997.
DOI : 10.1212/WNL.48.1.103

M. Hamon and S. Bourgoin, Implications de la sérotonine et d'autres molécules neuroactives dans la physiopathogénie de la migraine. Hypothèses actuelles, Pathol Bio!, vol.48, pp.619-629, 2000.

R. Hargreaves, Pharmacology and potential mechanisms of action of rizatriptan *, Cephalalgia, vol.126, issue.Supplement 1, pp.2-9, 2000.
DOI : 10.1016/S0014-2999(97)83024-5

P. Henry, G. Duru, G. Chazot, J. Dartigues, and G. Le, La migraine en France. Etude épidémiologique, impact socio-économique et qualité de vie, 1993.

K. Holroyd, D. Penzien, and G. Cordingley, Propranolol in the Management of Recurrent Migraine: A Meta-analytic Review, Headache: The Journal of Head and Face Pain, vol.31, issue.5, pp.333-340, 1991.
DOI : 10.1111/j.1526-4610.1991.hed3105333.x

S. Jenkins, Botulinum toxine type A as a migraine preventive treatment, Headache, vol.40, pp.445-450, 2001.

A. Klassen, A. Elkind, M. Asgharnejad, and C. Webster, Naratriptan is Effective and Well Tolerated in the Acute Treatment of Migraine. Results of a Double-Blind, Placebo-Controlled, Parallel-Group Study, Headache: The Journal of Head and Face Pain, vol.37, issue.10, pp.640-645, 1997.
DOI : 10.1046/j.1526-4610.1997.3710640.x

M. Lantéri-minet, H. Alchaar, and G. Besson, Etude pharmaco-épidémiologique sur le traitement de fond de la migraine. Enquête nationale sur les attitudes de prescription des omni-praticiens et des neurologues français, Rev Neural, vol.156, issue.12, pp.1106-1112, 2000.

M. Lantéri-minet, C. Lucas, and L. Leroy, Caractéristiques des patients migraineux, Pathol Bio!, vol.4, pp.8-13, 2000.

M. Lantéri-minet, Les céphalées par abus médicamenteux, Pathol Bio!, vol.48, pp.707-714, 2000.

L. Jeun-ne and C. , Traitement prophylactique de la migraine, Pathol Bio!, vol.48, pp.690-696, 2000.

T. Leniger, M. Wiemann, D. Bingmann, A. Hufnagel, and U. Bonnet, Different effects of GABAergic anticonvulsants on 4-aminopyridine-induced spontaneous GABAergic hyperpolarizations of hippocampal pyramidal cells-implication for their potency in migraine therapy, Cephalalgia, vol.116, issue.6, pp.533-537, 2000.
DOI : 10.1016/0014-2999(92)90748-S

V. Limmroth, Z. Kazarawa, G. Fritsche, and H. Diener, Headache after frequent use of serotonin agonists zolmitriptan and naratriptan, The Lancet, vol.353, issue.9150, p.378, 1999.
DOI : 10.1016/S0140-6736(05)74950-3

P. Linton-dahlof, M. Linde, and C. Dahlof, [A vicious circle when headache medication is the cause of chronic headache. A well-planned ambulatory detoxication can result in dramatic improvement], Lakartidningen, vol.98, pp.26-27, 2001.

R. Lipton, W. Stewart, R. Ryan, J. Saper, S. Silberstein et al., Efficacy and Safety of Acetaminophen, Aspirin, and Caffeine in Alleviating Migraine Headache Pain, Archives of Neurology, vol.55, issue.2, pp.210-217, 1998.
DOI : 10.1001/archneur.55.2.210

C. Lucas, M. Lantéri-minet, and L. Leroy, FRAMIG (III) : comportements thérapeutiques des migraineux, pp.21-29, 2000.

A. Macgrégor, Migraine associated with menstruations, Funct Neural, vol.15, pp.143-153, 2000.

P. Mannivet, H. Soliman, J. Callebert, J. Laplanche, and J. Launay, Mécanismes bioclùrniques dans la physiopathologie migraineuse, Pathol Bio!, vol.48, pp.630-641, 2000.

H. Massion and . La-migraine, Traitements de fond, John Libbey Eurotext, pp.107-117, 1998.

H. Massion, Hormones féminines et migraine, Pathol Bio! (Paris), vol.48, pp.672-678, 2000.

H. Massion, Les traitements prophylactiques de la migraine, Rev Neurol (Paris), vol.156, pp.79-86, 2000.

H. Massion and M. Bousser, Bêta-bloquants et migraine, Pathol Bio!, vol.40, issue.4, pp.373-380, 1992.

D. Matchar, W. Young, and J. Rosenberg, Evidence-based guidelines for migraine headache in the primary care setting : pharmacological management of acute attacks, pp.1-58, 2000.

N. Mathew, M. Asgharnejad, M. Peykamian, and A. Laurenza, Naratriptan is effective and well tolerated in the acute treatment of migraine: Results of a double-blind, placebo-controlled, crossover study, Neurology, vol.49, issue.6, pp.1485-1490, 1997.
DOI : 10.1212/WNL.49.6.1485

N. Mathew, A. Rapoport, and J. Saper, Efficacy of Gabapentin in Migraine Prophylaxis, Headache: The Journal of Head and Face Pain, vol.40, issue.2, pp.119-128, 2001.
DOI : 10.1001/jama.267.1.64

W. Mcneely and K. Goa, Diclofenac-Potassium in Migraine, Drugs, vol.57, issue.6, pp.991-1003, 1999.
DOI : 10.2165/00003495-199957060-00016

P. Michel, P. Pariente, G. Duru, J. Dreyfus, H. Chabriat et al., MIG ACCESS: a population-based, nationwide, comparative survey of access to care in migraine in France, Cephalalgia, vol.16, issue.1, pp.50-55, 1996.
DOI : 10.1046/j.1468-2982.1996.1601050.x

G. Mick, Physiopathologie de la crise migraineuse et modes d'action des antimigraineux : dernières nouvelles du monde animal, Pathol Bio!, vol.48, pp.593-607, 2000.

N. Minton and J. Sawyer, Headache after frequent triptan use, The Lancet, vol.353, issue.9161, p.1363, 1999.
DOI : 10.1016/S0140-6736(05)74360-9

W. Mulleners, T. Whitmarsh, and T. Stenier, Noncompliance may render migraine prophylaxis useless, but once-daily regimens are better, Cephalalgia, vol.18, issue.1, pp.52-56, 1998.
DOI : 10.1046/j.1468-2982.1998.1801052.x

J. Pascual, R. Munoz, and R. Leira, An open preference study with sumatriptan 50 mg and zolmitriptan 2.5 mg in 100 migraine patients, Cephalalgia, vol.8, issue.6, pp.680-684, 2001.
DOI : 10.1111/j.1526-4610.1999.00006.x

A. Peikert and C. Wilimzig, Prophylaxis of Migraine with Oral Magnesium: Results from a Prospective, Multi-Center, Placebo-Controlled and Double-Blind Randomized Study, Cephalalgia, vol.16, issue.4, pp.257-263, 1996.
DOI : 10.1046/j.1468-2982.1996.1604257.x

C. Perry, A. Markham, and . Sumatriptan, An updated review of its use in migraine, Drugs, vol.6, pp.889-922, 1998.

V. Pfaffenrath, G. Cunin, G. Sjonell, and S. Prendergast, Efficacy and Safety of Sumatriptan Tablets (25 mg, 50 mg, and 100 mg) in the Acute Treatment of Migraine: Defining the Optimum Doses of Oral Sumatriptan, Headache: The Journal of Head and Face Pain, vol.38, issue.3, pp.184-190, 1998.
DOI : 10.1046/j.1526-4610.1998.3803184.x

V. Pfaffenrath, P. Wessely, and C. Meyer, Magnesium in the prophylaxis of migraine-a double-blind, placebo-controlled study, Cephalalgia, vol.16, issue.6, pp.436-440, 1996.
DOI : 10.1046/j.1468-2982.1996.1606436.x

A. Pradalier and H. Ollat, Migraine and alcohol, Headache Quart, vol.2, pp.177-186, 1991.

A. Pradalier and D. Vincent, Migraine et anti-inflammatoires non stéroïdiens, Pathol Bio!, vol.40, pp.397-405, 1992.

N. Ramadan, S. Silberstein, F. Freitag, T. Gilbert, and B. Frishberg, Evidence-based guidelines for migraine headache in the primary care setting : pharmacological management for prevention of migraine

A. Rapoport, N. Ramadan, and J. Adelman, Optimizing the dose of zolmitriptan (Zomig,* 311C90) for the acute treatment of migraine: A multicenter, double-blind, placebo-controlled, dose range-finding study, Neurology, vol.49, issue.5, pp.1210-1218, 1997.
DOI : 10.1212/WNL.49.5.1210

F. Sakai, Safety and tolerability of rizatriptan *, Cephalalgia, vol.53, issue.Supplement 1, pp.16-19, 2000.
DOI : 10.1046/j.1526-4610.1998.3810764.x

J. Saper, The use of rizatriptan in the treatment of acute, multiple migraine attacks, Neurology, vol.55, pp.15-18, 2000.

K. Schmuck, C. Ullmer, H. Kalkman, A. Probst, and H. Lbbert, Receptors: An Early Step in the Generation of Migraine Headache?, European Journal of Neuroscience, vol.ii, issue.Suppl. 2, pp.959-967, 1996.
DOI : 10.1111/j.1460-9568.1996.tb01583.x

J. Schoenen, Traitements antirnigraineux : présent et avenir, Rev Med Liege, vol.54, issue.2, pp.79-86, 1999.

J. Schoenen, When Should Triptans be Taken During a Migraine Attack?, CNS Drugs, vol.123, issue.8, pp.583-587, 2001.
DOI : 10.2165/00023210-200115080-00001

J. Schoenen, J. Jacquy, and M. Lenaerts, Effectiveness of high-dose riboflavin in migraine prophylaxis A randomized controlled trial, Neurology, vol.50, issue.2, pp.466-470, 1998.
DOI : 10.1212/WNL.50.2.466

H. Schrader, L. Stovner, G. Helde, T. Sand, and G. Bovim, Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study, BMJ, vol.322, issue.7277, pp.19-22, 2001.
DOI : 10.1136/bmj.322.7277.19

C. Shelton and J. Connelly, Valproic Acid: A Migraine Prophylaxis Alternative, Annals of Pharmacotherapy, vol.43, issue.7-8, pp.865-866, 1996.
DOI : 10.1001/archneur.1995.00540270077022

S. Silberstein and . Methysergide, Methysergide, Cephalalgia, vol.18, issue.7, pp.421-435, 1998.
DOI : 10.1046/j.1468-2982.1998.1807421.x

M. Smits, Y. Van-der-meer, J. Pfeil, J. Rijnierse, and A. Vos, Perimenstrual Migraine: Effect of Estraderm TTS(r) and the Value of Contingent Negative Variation and Exteroceptive Temporalis Muscle Suppression Test, Headache: The Journal of Head and Face Pain, vol.34, issue.2, pp.103-106, 1993.
DOI : 10.1111/j.1526-4610.1994.hed3402103.x

G. Solomon, Verapamil in Migraine Prophylaxis - A Five-Year Review, Headache: The Journal of Head and Face Pain, vol.29, issue.7, pp.425-427, 1989.
DOI : 10.1111/j.1526-4610.1989.hed2907425.x

G. Solomon, R. Cady, and J. Klapper, Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine, Neurology, vol.49, issue.5, pp.1219-1225, 1997.
DOI : 10.1212/WNL.49.5.1219

G. Solomon, J. Steel, and L. Spaccavento, Verapamil Prophylaxis of Migraine, JAMA, vol.250, issue.18, pp.2500-2502, 1983.
DOI : 10.1001/jama.1983.03340180054025

G. Solomon, J. Steel, and L. Spaccavento, Traitement préventif de la migraine par le vérapamil, JAMA, vol.9, issue.78, pp.104-115, 1984.

C. Spencer, N. Gunasekara, C. Hills, and . Zolmitriptan, Zolmitriptan, Drugs, vol.58, issue.2, pp.347-374, 1999.
DOI : 10.2165/00003495-199958020-00016

E. Spierings, B. Gomez-mancella, D. Grosz, C. Rowland, F. Whaley et al., Oral Almotriptan vs Oral Sumatriptan in the Abortive Treatment of Migraine, Archives of Neurology, vol.58, issue.6, pp.944-950, 2001.
DOI : 10.1001/archneur.58.6.944

T. Steiner, F. Ahmed, L. Findley, E. Macgregor, and M. Wilkinson, S-fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study, Cephalalgia, vol.18, issue.5, pp.283-286, 1998.
DOI : 10.1046/j.1468-2982.1998.1805283.x

D. Stephen, M. Silberstein, and W. Young, Practice parameter : appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus (Summary statement) Report of the Quality Standarts Subcommittee of the American Academy ofNeurology, Neurology, vol.45, pp.585-587, 1995.

D. Stephen and M. Silberstein, The pharmacology of ergotamine and dihydroergotamine, Headache, vol.37, pp.15-25, 1997.

W. Stewart, R. Lipton, and J. Liberman, Variation in migraine prevalence by race, Neurology, vol.47, issue.1, pp.52-59, 1996.
DOI : 10.1212/WNL.47.1.52

P. Tfelt-hansen and R. Ryan, Oral therapy for migraine : Comparisons between rizatriptan and sumatriptan. A review of four randomized, double-bind clinical trials, Neurology, pp.55-74, 2000.

P. Tfelt-hansen, D. Vries, P. Saxena, and P. , Triptans in migraine. A comparative review of pharmacology, pharmacokinetics and efficacy, Drugs, issue.6, pp.601259-1287, 2000.
DOI : 10.2165/00003495-200060060-00003

P. Tfelt-hansen, P. Saxena, and C. Dahlof, Ergotamine in the acute treatment of migraine: A review and European consensus, Brain, vol.123, issue.1, pp.9-18, 2000.
DOI : 10.1093/brain/123.1.9

G. Tomkins, J. Jackson, O. Malley, P. Balden, E. Santoro et al., Treatment of chronic headache with antidepressants: a meta-analysis11Disclaimer: The views in this article reflect those of the authors and are not intended to represent in any way those of the U.S. Army or the Department of Defense., The American Journal of Medicine, vol.111, issue.1, pp.54-63, 2001.
DOI : 10.1016/S0002-9343(01)00762-8

T. Treves, A. Kuritzky, R. Hering, and A. Korczyn, Dihydroergotamine Nasal Spray in the Treatment of Acute Migraine, Headache: The Journal of Head and Face Pain, vol.38, issue.8, pp.614-617, 1998.
DOI : 10.1046/j.1526-4610.1998.3808614.x

. Vidal, Dictionnaire des médicaments. 7ime édition, Paris : Editions OVP, 2001.

B. Vogler, M. Pittler, and E. Ernst, Feverfew as a preventive treatment for migraine: a systematic review, Cephalalgia, vol.18, issue.10, pp.704-708, 1998.
DOI : 10.1046/j.1468-2982.1998.1810704.x

K. Vyas, R. Halpin, and L. Geer, Disposition and pharmacokinetics of antimigraine drug, rizatriptan, in humans, Drug Metab Dispo, vol.28, issue.1, pp.89-95, 2000.

S. Wilkinson, W. Becker, and J. Heine, Opiate Use to Control Bowel Motility May Induce Chronic Daily Headache in Patients With Migraine, Headache: The Journal of Head and Face Pain, vol.28, issue.3, pp.303-309, 2001.
DOI : 10.1046/j.1526-4610.1998.3801043.x